Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can they bring Otenaproxesul to market?

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 24, 2021 2:56pm

173 Views

Post# 33445111

RE:RE:Can they bring Otenaproxesul to market?

Forestview wrote: the patents to the drugs have ended. Hence them adding the H2S. So, it's legitimate.

Exactly - and generic drugs like Naproxen attached to a hydrogen sulfide releading component will create a new molecule that can be protected.

We are using ...
Naproxen for OTENA (ATB-346)
Ketoprofin for ATB-352
Aspirin for ATB-340
Mesalimine for the new IBD drug (and the old ATB-429/428 drugs)

Hoping that we're using Rivatigmine for a future AD/PD drug.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta